The opioid receptor like (ORL1) receptor is a G-protein coupled receptor superfamily, and regulates a plethora of neurophysiological functions. The structural requirements for receptor activation by its endogenous agonist, nociceptin (FGGFTGARKSARKLANQ), differ markedly from those of the κ-opioid receptor and its putative peptide agonist, dynorphin A (YGGFLRRIRPKLKWDNQ). In order to probe the functional architecture of the ORL1 receptor, a molecular model of the receptor has been built, including the TM domain and the extra-and intracellular loops. An extended binding site able to accommodate nociceptin-(1-13), the shortest fully active analogue of nociceptin, has been characterized. The N-terminal FGGF tetrapeptide is proposed to bind in a highly conserved region, comprising two distinct hydrophobic pockets in a cavity formed by TM helices 3, 5, 6 and 7, capped by the acidic second extracellular (EL2) loop controlling access to the TM elements of the peptide binding site. The nociceptin conformation provides for the selective preference of the ORL1 receptor for nociceptin over dynorphin A, conferred by residue positions 5 and 6 (TG versus LR), and the favourable interaction of its highly positively charged core (residues 8-13) with the EL2 loop, thought to mediate receptor activation. The functional roles of the EL2 loop and the conserved N-terminal tetrapeptide opioid 'message' binding site are discussed in the context of the different structural requirements of the ORL1 and κ-opioid receptors for activation. Keywords: molecular modelling/G-protein coupled receptor/ opioid receptor like 1 (ORL1) receptor/neuropeptide/nociceptin/structure-activity relationships
Introduction
The opioid receptor like (ORL1) receptor is a G-protein coupled receptor belonging to the opioid receptor family, as evidenced by an average shared sequence identity of~61% with the µ-, δ-and κ-opioid receptor types (Figure 1 ). Its natural agonist, nociceptin (Meunier et al., 1995) or orphanin FQ (Reinscheid et al., 1995) , is a highly basic heptadecapeptide (FGGFTGARKSARKLANQ) that closely resembles the putative natural κ-opioid receptor agonist, dynorphin A, which is also a cationic heptadecapeptide (YGGFLRRIRPKLKWDNQ), comprising six common amino acid residues (underlined). In common with the functional coupling of opioid receptors, activation of the ORL1 receptor by nociceptin causes inhibition of cAMP synthesis (Meunier et al., 1995; Reinscheid et al., 1995) , and of voltage-gated calcium channels (Connor et al., 1996) , and stimulation of an inwardly rectifying potassium conductance (Vaughan and Christie, 1996) . These similarities, both at the molecular and cellular level, are not however reflected in vivo since nociceptin produces pharmacological effects that sometimes differ, and even oppose those of opioids (reviewed recently by Henderson and McKnight, 1997; Meunier, 1997; Darland et al., 1998) . For instance, in contrast to the analgesic effects of opioid receptor agonists, nociceptin stimulation of the ORL1 receptor can result in hyperalgesia (Meunier et al., 1995; Reinscheid et al., 1995) , and/or inhibition of stress-and opioid-induced analgesia (Mogil et al., 1996a,b) .
Studies of the structure-activity relationships of nociceptin using truncated nociceptin derivatives (Dooley and Houghten, 1996; Reinscheid et al., 1996; Butour et al., 1997; Guerrini et al., 1997) and/or nociceptin-dynorphin A hybrid peptides (Lapalu et al., 1997; Reinscheid et al., 1998) have led to the conclusion that the functional architectures of nociceptin and dynorphin A are different. Most significant in this respect is that the shortest fully active fragment of nociceptin, nociceptin-(1-13)NH 2 (Dooley and Houghten, 1996; Guerrini et al., 1997) , is somewhat longer than the shortest fully active fragment of dynorphin A, dynorphin A-(1-6 or 7) (Mansour et al., 1995; Chavkin and Goldstein, 1981) . Thus the positively charged core of the peptide appears to be a more necessary requirement for biological activity of nociceptin than of dynorphin A. This conclusion has received strong support with the identification of a cationic hexapeptide, NAc-RYYRWK-NH 2 , that not only interacts with the ORL1 receptor with as high an affinity as nociceptin itself, but is also a more potent agonist (Dooley et al., 1997) . Moreover, unlike the ORL1 and κ-opioid receptors which show substantial preference for nociceptin and dynorphin A, respectively, certain κ-opioid-ORL1 chimeric receptors have recently been observed to bind both nociceptin and dynorphin A with high affinity, and to be activated by the two neuropeptides with equal efficacy (Lapalu et al., 1998 ; Mollereau,C., Moulédous,L., Lapalu,S., Cambois,G., Moisand,C., Butour,J.-L. and Meunier,J.-C., manuscript submitted), providing a further indication that nociceptin and dynorphin A bind and activate their parent receptors in different ways.
In order to gain a better understanding of the molecular interactions between the ORL1 receptor and nociceptin, we have modelled the receptor, and its complex with the endogenous ligand. A highly conserved N-terminal tetrapeptide binding site region, comprising two adjacent hydrophobic pockets in a cavity formed by TM helices 3, 5, 6 and 7, has been characterized. The sidechain of the N-terminal phenylalanine of nociceptin can be accommodated in the more deeply sunk pocket, close to the conserved aspartate (130) in the TM3 helix. The modelled nociceptin conformation is consistent with Mollereau et al., 1994) with those of the κ-(OPRK_HUMAN; Mansson et al., 1994) , µ-(OPRM_HUMAN; Wang et al., 1994a ) and δ-(OPRD_HUMAN; Knapp et al., 1994) opioid receptor types was performed manually. Consecutive numbering systems for the individual receptors are denoted. Insertion sites in the ORL1 receptor sequence are denoted using a system of upper case italicized letters (A, B, . . .) . Conserved residues are shown in bold typeface, and the half-cystine residue positions of the conserved disulphide bridge are also underlined. The (EL1-3) extra-and intra-cellular (IL1-3) loop regions (Ͻ···Ͼ), delimited by the seven transmembrane (TM1-7) helices (ϭ) used in modelling of the ORL1 receptor (see Computational methods), are named in accordance with the accepted convention. Corresponding TM helix regions (Baldwin, 1993) in the bovine rhodopsin sequence (OPSD_BOVIN; Ovchinnikov, 1982) , are also indicated. Completely conserved residue positions, used to align the bovine rhodopsin and the opioid receptor sequences, are indicated in bold lettering.
the selective preference of the ORL1 receptor for this peptide ligand over dynorphin A, conferred by positions 5 and 6 and provides for the favourable interaction of its highly positively charged core (8-13) with the acidic EL2 loop. The functional roles of the extracellular loop domain and the conserved N-terminal tetrapeptide opioid 'message' binding site are discussed in the context of the different structural requirements of the ORL1 and κ-opioid receptors for activation. The model provides a basis for further experimental investigation of the interplay of structure and biological function in this important receptor.
Computational methods

Molecular modelling tools
With the exception of helix rotation which was performed using the Insight II 95.0 package (Biosym/MSI, San Diego), all interactive graphics manipulations were carried out using the SYBYL 6.3 (Tripos Inc.) program suite. Stagewise energy minimisation procedures used in the refinement of the ORL1 receptor structure and its complex with nociceptin were carried out using the SYBYL implementation of the Powell torsional gradient algorithm and the AMBER all-atom force field (Weiner et al., 1986) . Hydrogen atoms were added using the BIOPO-LYMER facility within SYBYL, and pre-minimized as necessary at each stage. The electrostatic model comprised a distantdependent dielectric constant with a non-bonded cut-off of 8 Å and an ε value of 4.
Modelling of ORL1 receptor transmembrane core
In the absence of a high resolution crystal structure for the G-protein coupled receptor (GPCR) superfamily, the bovine rhodopsin model of Herzyk and Hubbard (1995) was used as a template to construct the seven-helix transmembrane (TM) domain of the ORL1 receptor. Assignment of the seven TM helix regions in the cDNA-derived ORL1 receptor sequence (Mollereau et al., 1994) was based upon the GPCR sequence analysis of Baldwin (1993) . These were found to be in generally good agreement with predictions made by the PHDhtm (Rost et al., 1995) neural network program from a multiple sequence alignment, and with the appearance of charged residues at sequence alignment positions corresponding to external (lipid accessible) helix faces, as determined by PERSCAN v7.0 (Donnelly et al., 1993 Fourier transform periodicity analyses of amino acid residue properties (Table I ). An initial model of the ORL1 receptor was constructed by superposition of helices with ideal geometry onto the C α co-ordinates of the Herzyk and Hubbard (1995) template according to the sequence alignment with rhodopsin ( Figure 1 ). Visual inspection of the model indicated that five (1, 3, 5-7) TM helices were appropriately orientated with ligand accessible residues, as deduced from collated single point site-directed mutagenesis data for the opioid receptor structural family (Table II) , on the inside of the helical bundle. TM helices 2 and 4 were rotated around their axes by ϩ50°and ϩ90°, respectively, when viewed from the extracellular surface, to best satisfy this criterion. Checks were also made that the model adequately met inter-helical residue proximity constraints, inferred from correlated site-directed mutagenesis studies of several GPCR systems (Table III) .
In the next stage of model building, the helices were extended by one turn at either end, and the sidechain conformations manually adjusted to relieve poor non-bonded steric contacts and to optimize potentially favourable sidechainsidechain and sidechain-mainchain interactions. Following the pre-minimization of added hydrogen atoms, residue sidechains were energy minimized to a r.m.s. energy gradient of 0.05 kcal mol -1 Å -1 with all mainchain atoms held fixed. The entire TM core region was then minimized to a final r.m.s. energy gradient of 0.1 kcal mol -1 Å -1 in the absence of any positional constraints. All the residues in the helical extensions were then excised apart from Cys123 at the interface of the first extracellular loop (EL1) and the third TM helix. The r.m.s.d. Fourier transform analyses of helical periodicity were performed using the PERSCAN (v 7.0) program suite (Donnelly et al., 1993 . Calculations were performed on a manually aligned set of sequences from putative TM helical regions in (a) 20 peptide receptor families and (b) a subset comprising members of the opioid family, and close relatives from the somatostatin, angiotensin type 1 and chemokine families. Periodicity profiles were calculated for two properties (U): residue conservation (C) and substitution patterns (S), determined from a difference matrix for lipidaccessible residues and buried residues in water-soluble proteins (Overington et al., 1992; Donnelly et al., 1993 (Komiya et al., 1988; Donnelly et al., 1993) . The direction of the internal face of the predicted helix was estimated from the angle (Θ U max ) describing the property moment relative to a reference residue position in the sequence alignment. Helix orientation in the final receptor model (Θ I max ) was similarly calculated from the sidechain inaccessibility (Lee and Richards, 1971 ) moment with respect to the same reference residue position. Differences in orientation, (Θ I max -Θ U max ), correspond to the view from the extracellular surface, and indicate rotations of helices in the final model that would be required to give an exact match with the predictions from the sequence alignments (cf. Figure 2) . Residues on the (predicted) external ORL1 receptor helix faces where at least one charged residue appears at the same position in the sequence alignments serve as an indicator of the points at which helices protrude from the lipid bilayer on the extracellular (E) and intracellular (I) sides . Those within the lipid bilayer itself, operationally defined as 12 central residue positions of the 26-residue transmembrane helices of Baldwin (1993) , are denoted TM. Predictions of TM helical regions from the PHDhtm profile-based neural network analysis (Rost et al., 1995) of the multiple sequence alignment generated upon submission of the full ORL1 receptor sequence (Mollereau et al., 1994) to the PredictProtein mail-server (PredictProtein@EMBL-heidelberg.de) are detailed together with the regions delimited by Baldwin (1993) used to construct the model. c TM helix 3 has been extended by one residue at the N-terminus. Mansour et al. (1997) Single-site mutants with significantly altered agonist or antagonist binding and/or bioactivity properties are listed. Sidechain positions of (equivalent) residues in the ORL1 receptor model are orientated towards the centre of the transmembrane helical bundle (cf. Figure 2 ).
with respect to equivalent C α positions in the bovine rhodopsin model template was 1.41 Å, and 0.26 Å when TM helices 2 and 4 were removed from the calculation.
Modelling extra-and intracellular loops in the ORL1 receptor
The six loop sections interconnecting successive TM helices (see Figure 1 ) of the minimized receptor core framework were then added. With the exception of EL2, which was mainly manually built by an iterative process of interactive graphics and energy minimization, ensembles of candidate loop fragments compatible with the geometry of a three-residue overlap with the TM model core were first identified from a database of Ͼ1100 protein structures sharing up to 95% sequence identity using the COMPOSER protein modelling suite (Sutcliffe et al., 1987a,b; Blundell et al., 1988; Topham et al., 1990; Srinivasan and Blundell, 1993) . Protein fragments were joined to the core using a ring closure algorithm (F.Eisenmenger, personal communication), or where this resulted in significant changes to the internal loop geometry, melded directly to the framework (Blundell et al., 1988; Sutcliffe, 1988) . Minor adjustments in sidechain conformations were made where necessary, before minimization of individual loops to an r.m.s. energy gradient of 0.05 kcal mol -1 Å -1 . Mainchain atoms of the TM core were normally held fixed, but flanking residues were occasionally released to facilitate convergence. Fresh copies of the minimized TM region coordinates were used to process the loops. Candidate loop coordinate sets were excised and stored for later display. The first stage in modelling of the EL2 loop was the construction of the conserved disulphide bridge connecting Cys123, at the N-terminus end of TM helix 3, and Cys200 in the EL2 loop (Figure 1 ). The bridge was built using one of the nine preferred sidechain rotamer combinations detailed by Srinivasan et al. (1990) : χ 1 Cys123 ϭ -60°, χ 2 Cys123 ϭ ϩ75°, χ 1 Cys200 ϭ -60°, χ 2 Cys200 ϭ -70°, and χ ss ϭ ϩ90°. The peptide chain was manually extended by one residue on the C-terminal side of Cys200 and three residues on the other side, aided by the SYBYL peptide building module. Residues in low potential energy conformations were also added by hand to the termini of TM helices 4 and 5. Connecting peptide fragments were then sought in the protein database using COMPOSER for a seven-residue (202-208) section (see Table IV ), and a shorter section (194) (195) (196) on the N-terminal side of the disulphide bridge. Sequence alignment shows hydrophobic residues at positions 198 and 202 (ORL1 receptor numbering) in the opioid receptor family (Figure 1 ). Torsion angle adjustments were made in order to maximize the buried surface area of the sidechains of Ile198 and Val202, calculated according to Lee and Richards (1971) . Further structural modifications to the loop and sidechain conformations of residues in the TM core were made to avoid trapping of the loop in a high energy local minimum during minimization. Harmonic distance and dihedral angle constraints were introduced to maintain the structural integrity of the disulphide bridge, and to ensure good proline geometry at positions 205 and 207. The constraints were gradually released, and the EL2 loop minimized to a final r.m.s. energy gradient of 0.05 kcal mol -1 Å -1 . As before, sidechain atoms of the TM framework were free to move, but the mainchain was held fixed.
Final model refinement
Once all the loop sections had been assembled, they were simultaneously displayed together with the minimized TM region co-ordinates. A final selection of loop fragments was made (Table IV) on the basis of mutual conformational compatibility. Poor steric contacts between loops were relieved by manual tweaking of mainchain and sidechain torsion angles, before minimization of the intra-and extracellular loop domains as separate groups to an energy gradient of 0.05 kcal mol -1 Å -1 . The Table III 
9.5 Co-operative ligand binding.
8.8 Lys 296-Glu 113 salt bridge
6.9 disruption in G90D mutant: binding site.
Tertiary contact mapping by Yu et al. (1995) TM6/EL3 F276 G287 di-sulphide bridge formation
Engineered Zn 2ϩ binding site. Elling et al. (1996) TM5/EL2
Engineered Zn 2ϩ binding site. Elling et al. (1996) TM3
The compendium indicates ORL1 receptor residue positions in different structural elements that can be expected to be proximal (cf. Figure 3 ). The inter-atomic distances correspond to the unliganded receptor structure. Inter-atomic distances in the ORL1-nociceptin complex do not differ significantly. Definitions of the structural elements are given in Figure 1 . Operational definitions and residue numbering of structural elements in the ORL1 receptor are given in Figure 1 . Protein fragments are numbered according to the Brookhaven Protein Data Bank co-ordinate files (Bernstein et al., 1977; Abola et al., 1987) , identified by the four-letter code and, where applicable chain identifier, shown in parentheses. a R.m.s. deviations refer to main-chain C α positions. b Residues 113-117 in EL1 (underlined) were remodelled using a 'collar' extension procedure (see Srinivasan and Blundell, 1993) in which a five-residue fragment originating from the casein kinase 1 (1CSN, 95-107) was removed, and a more suitable fragment from penicillopepsin (3APP, 143-151), inserted. c Flanking EL2 loop residues (191-201; 209-213) were manually built. d Loop melding procedure (Sutcliffe, 1988) used.
loop mainchain atoms were first held fixed, and then released, and the minimization re-started. Mainchain atoms of the TM core were held fixed throughout, but sidechain atoms were free to move. A copy of the receptor co-ordinates was kept at this point (stage 1), before final energy minimization to a r.m.s. convergence gradient of 0.1 kcal mol -1 Å -1 in the absence of any positional constraints (stage 2).
In situ modelling of nociceptin binding to the ORL1 receptor
Construction of the nociceptin-ORL1 receptor complex started with the manual docking of selected amino acid residues into the refined (stage 2) receptor molecule, guided by site-directed mutagenesis and other experimental data. Inspection of the ORL1 receptor model revealed the presence of two hydrophobic pockets in a cavity formed by TM helices 3, 5, 6 and 7, corresponding to the conserved transmembrane opioid binding site mapped in the δ- (Befort et al., 1996a,b) and µ-receptors (Mansour et al., 1997) . Both pockets are conserved to a large extent in the ORL1 receptor, and Feng et al. (1998) have shown that mutation of five residues in this vicinity (Ala216, Val279, Gln280, Val281 and Thr305) to their entirely conserved opioid receptor counterparts will restore a functional opioid binding site. On the basis of the clear similarity between the N-terminal FGGF sequence of nociceptin and the opioid YGGF 'message' sequence, nociceptin-(1-4) can be assumed to bind in the vestigial 'opioid binding pocket' of the ORL1 receptor, with the sidechains of F1 and F4 occupying the two aromatic pockets. Mutation of Gln280, which is located on the rear wall of the F1 pocket in TM helix 6, to histidine, increases the affinity of the ORL1 receptor for lofentanil by eightfold (Mollereau et al., 1996) . Most probably the lofentanil phenylpropanamide group binds in the F1 pocket, enabling the protonated (N 1 ) piperidine ring nitrogen to hydrogen bond with the entirely conserved Asp130 in TM helix 3. The increase in affinity of the Q280H mutant can then be ascribed to improved electrostatic interactions of the carbonyl oxygens of the phenylpropanamide moiety and the COOCH 3 substituent at position 4 of the piperidine ring with the histidine imidazole ring. ComettaMorini et al. (1992) have shown both oxygens to be good proton accepting centres in AM1 semi-empirical quantum mechanics calculations. The presence of physically analogous groups in lofentanil and the protonated nociceptin F1 residue suggests that they might adopt similar spatial dispositions in ligand complexes with the receptor. The protonated nitrogen, carbonyl carbon and phenyl ring centroid of phenylalanine of the (χ 1 ϭ 180°; χ 2 ϭ 90°) sidechain rotamer can be fitted to the N 1 , COOCH 3 carbonyl carbon and phenylpropanamide ring centroid of a HF/6-31G* geometry optimized lofentanil structure (C.M.Topham and G.Poda, unpublished results) with an r.m.s.d. of 0.62 Å. A phenylalanine residue with this sidechain conformation was therefore docked into the receptor with the F1 carbonyl group orientated towards Gln280, and the protonated nitrogen donating a hydrogen bond to the Asp130 sidechain. A second phenylalanine residue (F4) was positioned in the other hydrophobic pocket closer to the extracellular surface, separated from the F1 pocket by Phe220. The two residues were then linked by glycines, and the N-terminal FGGF tetrapeptide energy minimized, with the receptor sidechains free to move, and harmonic distance constraints imposed to maintain hydrogen bonding to Asp130.
The positively charged nociceptin-(8-13) core, carrying arginines at positions 8 and 12, the replacement of which by uncharged residues adversely affects nociceptin affinity and activity (Dooley and Houghten, 1996; Reinscheid et al., 1996; Lapalu et al., 1997) , is assumed to interact with the acidic EL2 loop, shown to be essential for activation by nociceptin (Mollereau,C., Moulédous,L., Lapalu,S., Cambois,G., Moisand,C., Butour,J.-L. and Meunier,J.-C., manuscript submitted). The nociceptin-(12-14) section (RKL) was manually built into the surface cavity bounded by the EL2 loop such that the sidechains of R12 and K13 were able to ion pair with glutamate residues 196 and 194, respectively, and the L14 sidechain packed in between Pro207 and Tyr210. The tripeptide was energy minimized in situ with the backbone atoms of the receptor held fixed. Potential seven-residue (5-11) connecting fragments with satisfactory three-residue overlap geometry were then searched for in the protein structure database using COMPOSER. These were simultaneously displayed, and a fragment selected that clashed least with the receptor. A threeresidue (15-17) tailpiece was added, and capped with an NMe group to eliminate C-terminus charge effects in a part of the ligand known not to be important for biological activity.
A stagewise refinement procedure was adopted in order to identify an energy minimum for nociceptin-(1-17), whilst causing minimum disturbance to the transmembrane core of the receptor. Selected adjustments in sidechain conformations of the peptide and the receptor were first made, before energy minimization of the ligand to an energy gradient of 0.15 kcal mol -1 Å -1 with the mainchain atoms of the receptor held fixed, but the sidechains free to move. The entire system was then minimized to an energy gradient of 0.05 kcal mol -1 Å -1 without positional restraints. The nociceptin molecule was excised and docked back into a copy of the refined (stage 2) apo-receptor co-ordinate set, and the procedure repeated twice more. All three extracellular loops were then removed and melded back onto a stage 1 copy of the receptor TM core (plus intracellular loops), by energy minimization to a gradient of 0.05 kcal mol -1 Å -1 with the remaining receptor backbone atoms held fixed. The refined peptide ligand was docked once more into the receptor, and additional minor changes made to sidechain conformations. The extracellular loops were then re-minimized to a r.m.s. energy gradient of 0.1 kcal mol -1 Å -1 with both the nociceptin and remaining receptor backbone atoms held fixed, and all sidechains free to move. Finally the entire system was energy minimized to a r.m.s. gradient of 0.1 kcal mol -1 Å -1 in the absence of any positional constraints.
Structure-sequence fitness of loop regions
Compatibility of the modelled ORL1 receptor loop regions with their primary sequences was determined using the window averaging facility in the HARMONY (v 0.7) computer program (Topham et al., 1994) , incorporating a modified scoring system described below. Environment-dependent amino acid propensities are assigned at each position in a protein fold from a [216 structural environment (ε j )ϫ21 residue type (r i )] twodimensional table. The propensity table was calculated from observed frequencies of unique residue/environment combinations at alignment positions in a structural alignment database release 5a Š ali and Overington, 1994) . Conditional probabilities of finding a particular residue type in a given environment, p(r i /ε j ), are calculated by correcting for the normalized frequency of residue type occurrence in the global data set and smoothing of the environmentdependent probabilities (Topham et al., 1994) . A total of 72 451 residue occurrences were recorded using the full 1169 database comprising 576 proteins/protein domains in 126 families, following removal of two membrane protein families. In common with statistical mechanics treatments of observed frequencies of occurrence of amino acid sequence and structural features in proteins (Sippl, 1993a,b; Rooman and Wodak, 1995) , the propensities are now first compared to a suitable reference state, logarithmically transformed and then summed over the length of the entire fold:
where N ij is the number of residues of type i in environment j, and p(r i ) is the probability of finding a residue i in any environment, and is the same for all residue types (i.e. 1/21 ϭ 0.046) since the residue propensities are pre-adjusted for the normalized frequency of residue type occurrence in the global data set. In the case of a globular protein, the sequence/structure fitness of the overall fold can be assessed by comparing the summed score, (E (Σ) score ), against a calibration curve constructed using experimentally determined structures. Application of this approach, in which environmental propensities have been calculated from a data set of soluble proteins, would be inappropriate for a membrane protein. However, the environmental features of hydrogen bonding, sidechain accessibility and seven mainchain conformational classes outside of secondary structural elements (Topham et al., 1993) used to calculate the propensity table are all local in nature. Plots of E (Σ) score as a function of chain length are linear, pass close to the origin, and do not show significant protein size-dependent effects that would be expected to result from the use of longer range physical features such as, for example, inter-residue distance as a function of linear separation in the amino acid sequence. It is therefore possible to calculate a meaningful average residue score (E (Av.) score ) from the calibration curve, and this may reasonably be used to assess the structural integrity of loop regions at the receptor surface. A best-fit E (Av.) score value of 0.65 per residue was determined from an unweighted linear regression analysis (r ϭ 0.97) using a calibration set of high resolution crystallographic structures (Topham et al., 1994) .
The conformational structural integrity of loop regions can be probed using by averaging propensity scores (E (n) score ) at all positions in a moving window of length n, provided that n is sufficiently small so as not to be unduly influenced by contributions from residues in the transmembrane regions. Values of (E (5) score ) were calculated at the centre (k ϭ 0) of each (n ϭ 5) five-residue window:
and plotted as a function of loop residue position.
Results
Experimental support for the ORL1 receptor model
A three-dimensional structure of the human ORL1 receptor (residues 50-276) has been built. The receptor model is based largely on the TM helical bundle bovine rhodopsin template derived by Herzyk and Hubbard (1995) , with rotations applied to TM helices 2 (ϩ50°) and 4 (ϩ90°) during the early stages of modelling. The r.m.s. difference over 182 C α positions Fig. 2 . Triptic stereo view of the ORL1 receptor transmembrane helical bundle. Sidechains of (topologically equivalent) residues inferred from single point site-directed mutagenesis data as being important for opioid receptor family function (Table II) are shown in heavy typeface. The diagram was prepared using the SETORPLOT and SETOR programs (Evans, 1993) .
comprising the TM helix framework (Figure 1 ) of the aporeceptor compared with the starting template is 1.53 Å, and 1.64 Å for the receptor complexed with nociceptin. The seven TM helices are arranged sequentially and anti-clockwise when viewed from the extracellular surface ( Figure 2 ). Mutated residue positions in the ORL1 receptor or the three opioid receptors yielding significant (Ͼ14-fold) changes to either binding and/or activity properties with respect to at least one ligand-receptor system (Table II) are highlighted in Figure 2 . The residues are orientated towards the centre of the helical bundle, as would be expected in order for them to be accessible to ligand. The orientations of TM helix 4, 5, 6 and 7 are in good accord with the directions of residue substitution pattern moments, calculated from the peptide receptor multiple sequence alignments (Table I ) using the Fourier transform methods described by Donnelly et al. (1993 . When residue conservation is used to calculate helical periodicity, good agreement is obtained for TM helix 6, but is somewhat poorer for helices 4, 5 and 7 (yet still within 37-49°). The calculated property profile moments for TM helices 2 and 3 are less self-consistent, although in both cases best agreement with the model residue sidechain inaccessibility moment (to within 29°and 34°, respectively) is obtained for residue substitution pattern profiles using the full peptide GPCR sequence alignment data set. A clockwise rotation of TM helix 1 (viewed from the extracellular surface) by 51-59°w ould be required to obtain agreement with the residue property profile moments calculated from the sequence alignment. This however was not done in order to permit Leu59 to be orientated towards the centre of the TM bundle. Mutation of this residue to a serine abolishes binding of iodinated [Y14]-nociceptin to the ORL1 receptor (Meng et al., 1996) . Independent rotation of TM helix 1 would also adversely affect the proximity of the Tyr58 and Arg302 (TM helix 7) sidechains, shown in Figure 3 to be close to one another. Direct interaction of the corresponding Thr37 and His478 residues in TM helices 1 and 7 of the m5 muscarinic receptor has been demonstrated by point-site restoration of function in m2-m5 receptor chimera (Liu et al., 1995) .
The residue property profiles identify a number of lipid facing charged residue positions in the peptide GPCR alignments of TM helices 2, 3 and 4. However, charged residues do not occur at these positions in the ORL1 receptor sequence (Table I) , nor indeed do they in the model itself, as determined by Fourier transform analysis of relative sidechain accessibility Surface loops are shown in red, and the conserved disulphide bridge, connecting Cys200 (EL2) and Cys123 at the EL1 loop/TM3 helix interface (Figure 1) , in yellow. The highlighted (equivalent ORL1 receptor) residue clusters have been inferred to be proximal from site-directed mutagenesis experiments carried out in other GPCR systems (see Table III ). The image was produced using the SETOR and SETORPLOT molecular graphics programs (Evans, 1993). profiles. Taking the model sidechain accessibility profiles as a reference, prominently lipid-exposed residue positions carrying charged residues are observed in TM helix 2 of the vasopressinlike (at positions 91 and 92, ORL1 receptor numbering) and thrombin receptor families (position 92). None is observed in the other TM helices.
In addition to the proximal Tyr58-Arg302 residue pair, other inter-helical residue clusters, inferred from correlated sitedirected mutagenesis studies in a variety of GPCR systems, are present in the model (Figure 3) . Details of these clusters, together with selected inter-atomic distances in the aporeceptor, are summarized in Table III . The proximity of residues in several different TM helix pairs provides a valuable check on the relative positions of the helices, and therefore on the integrity of the receptor bundle. All of the TM helices apart from helix 4 are represented in at least one TM helix pair.
Structural features and geometry of the loop regions
Studies of structure-activity relationships in the nociceptin-ORL1 receptor system (Dooley et al., 1997; Guerrini et al., 1997; Lapalu et al., 1997) , and ligand selectivity in κ/ORL1 chimeric receptors (Lapalu et al., 1998 ; Mollereau,C., Moulédous,L., Lapalu,S., Cambois,G., Moisand,C., Butour,J.-L. and Meunier,J.-C., manuscript submitted) indicate that components of the extracellular loop domain, and in particular the EL2 loop, are involved in nociceptin binding and receptor activation. In view of their likely key role, the three extracellular (EL) loops have been built into the model (Figure 3 ). The EL1 loop forms a flat span between TM helices 2 and 3, with Cys123 of the conserved disulphide bridge located at the junction with TM helix 3. The longer and more variable EL2 loop, comprising seven acidic residues, is arranged around the edge of the cavity formed by TM helices 3, 5, 6 and 7, and proposed nociceptin N-terminal tetrapeptide binding site described below, to which it is clearly able to control access. Cys200, the disulphide bonded partner of Cys123, is located towards the middle of this loop. The disulphide sidechain geometry remained within the original conformational domain, and was assessed to be of the highest stereochemical grade by the MODIP program of Sowdhamini et al. (1989) . The disulphide bridge is buried, with Ͻ7% relative sidechain accessibility (Hubbard and Blundell, 1987) , as was also commonly found in a survey of high resolution protein crystal structures (Srinivasan et al., 1990) . The third extracellular loop (EL3) arches between TM helices 6 and 7, packing beneath the C-terminal portion of EL2. A network of potential hydrogen bonding interactions is observed between residues of the EL2 loop and residues of the other two extracellular loops. The three intracellular loops, connecting TM helices 1 and 2 (IL1), 3 and 4 (IL2), and 5 and 6 (IL3), are also shown in Figure 3 . Cross-over contacts have been made between residues at the N-terminal ends of IL2 and IL3, but alternative interactions between these loops are possible.
The overall model geometry was checked using PROCHECK (Laskowski et al., 1993) . No short non-bonded contacts were found, and the correct chirality was observed at all tetrahedral carbon atom centres. All 248 non-glycine and non-proline residues are within the 'most favoured' (90.7%), or 'additionally allowed' (9.3%) regions of the Ramachandran plot delineated by Morris et al. (1992) . The side-chain torsion angles were determined as being inside or better than the expected deviations from an ideal (globular) protein structure determined crystallographically at 2 Å resolution. Acceptable geometry was also obtained for the ORL1 receptor in the model complex with nociceptin, which was refined and minimized semiindependently: no residues were observed in either the 'disallowed' or 'generously allowed' regions of Morris et al. (1992) . The disulphide bridge geometry was again of the highest stereochemical grade according to the Sowdhamini et al. (1989) 
criteria.
A profiling method (Topham et al., 1994) , incorporating a modified scoring regime, has been used to assess the compatibility of the loop conformations with their primary sequences. Plots of the (E (5) score ) values as a function of residue position for the three extracellular loops are shown in Figure 4 . For the most part, the profiles comprise positive scores slightly less than the expected average score of ϩ0.65 for a residue in a similar sized globular protein. The negative scores in the residue range Leu113-Trp116 of the EL1 loop profile would normally be indicative of a poorly modelled section. The trough largely derives from the presence of solvent exposed residues at the heart of a run of nine non-polar or hydrophobic residues (ILLGFWPFG). However, this region which also contains a conserved residue quartet (WPFG), possibly contacts the 50-residue N-terminal domain absent from the model. Residue sidechains that are apparently accessible to solvent in the model may thus be buried in the native receptor protein. Two EL2 loop profiles are shown, corresponding to the unliganded and liganded receptor models, the nociceptin co-ordinates of the latter having been excised prior to the assignment of residue environments. A high scoring profile is obtained for the EL2 loop in the complex with nociceptin. The profile for the apo-receptor loop is very similar in the C-terminal region, but dips below zero in the N-terminal section. The improved profile for the liganded conformer is mainly attributable to an increase in solvent accessibility of the Glu197 sidechain which faces the centre of the receptor. Taken together with the geometric analyses, these results provide good evidence that the extracellular loop regions are in general conformationally compatible with their sequences. Profiles for the three intracellular loops are also shown in Figure 4 . Troughs occur in the profiles for the IL2 and IL3 loops, although these again correspond to exposed regions bearing hydrophobic residues, making interpretation difficult, since the G-protein and the receptor C-terminal domain are absent.
Interactions of nociceptin with the ORL1 receptor
Location of the proposed nociceptin binding site within the ORL1 receptor is shown in Figure 5 . The nociceptin backbone dihedral angles are all in acceptable regions of (φ, ψ) conformational space (Table V) . The N-terminal (FGGF) tetrapeptide is positioned within a cavity, formed by elements from TM helices 3 and 5-7, such that its protonated N-terminus can interact with the conserved aspartate residue (130) of the TM3 helix, as shown in an expanded view of the region (Figure 6) . A strikingly high proportion of the receptor residues falling within a 5 Å contact radius of nociceptin-(1-4) are entirely conserved in the opioid receptor family (Table VI) . The topology of the FGGF binding site is in good accord with the mapping of analogous opioid binding pockets, carried out using 'loss of function' site-directed mutagenesis approaches in the δ- (Befort et al., 1996a,b) and µ-receptors (Mansour et al., 1997) , and an inverse 'gain in function' approach in the ORL1 receptor itself (Feng et al., 1998) . Two transmembrane aromatic pockets are discernible. The nociceptin F1 sidechain has been docked into the deeper lying pocket, bounded by Tyr131, Met134, Phe220, Phe224, Trp276 and Val279. Of these residues, five are conserved in the opioid receptor family, and the valine at position 279 is conservatively replaced by isoleucine in the κ-, µ-and δ-opioid receptors. The F1 phenyl ring of nociceptin lies between the Phe220 and Trp276 aromatic ring systems, making favourable edge-face and displaced score ) of ϩ0.65 per residue for a correctly folded (277-residue) globular protein, calculated from a linear regression analysis (r ϭ 0.97) of summed scores as a function of sequence length for a set of high resolution protein structures. The lower solid horizontal baseline is the estimated mean per residue score of -0.27, corresponding to the random assignment of residue environment to residue type. This was similarly calculated from the linear regression parameters (slope ϭ -0.27Ϯ0.08; ordinate intercept ϭ 0.08Ϯ16.80) for the retrofolded protein set [see Topham et al. (1994) for operational definition]. The lower correlation coefficient (r ϭ 0.64) and increased parameter standard errors reflect the wider score distributions associated with non-native (high energy) configurations. A score of zero represents the unconditional probability of finding an amino acid residue in any (or all) environment(s), and serves as a reference by which to access structure-sequence fitness.
face-face stacking interactions, respectively, typical of those observed in known protein structures (Burley and Petsko, 1988; Hunter et al., 1991) . Two (non-conserved) polar residues, Ser223 and Gln280, also line the hydrophobic pocket, but only limited contact is made with the F1 phenyl ring. This is consistent with the unaltered binding properties and biological potency of the Q280H mutant ORL1 receptor with respect to nociceptin (Mollereau et al., 1996) .
Glycines 2 and 3 of nociceptin pack close to a number of conserved residues in TM helix 7 (Table VI) , and the carbonyl oxygen of G3 is able to accept a hydrogen bond from the conserved Tyr131 (Table VII ). An intra-molecular hydrogen bond (G3-NH·····OϭCϽ F1) further stabilizes the nociceptin conformation in this region. The F4 sidechain of nociceptin can be accommodated, angularly disposed with respect to the F1 phenyl ring in the adjacent hydrophobic pocket, closer to the extracellular surface and demarcated from the F1 pocket by the sidechain of Phe220, with which it makes an edgeface interaction (Figure 6 ). In addition to this residue, the second pocket again comprises several conserved (Tyr131 and Cys304), or conservatively varied residues, including Ile127 (conserved in the κ-and µ-receptors; leucine in the δ-receptor) (Figure 1) is also depicted. The binding site principally comprises elements from TM helices 3 and 5-7, that accommodate the N-terminal (1-6) portion of nociceptin, and the acidic second extracellular loop (EL2), with which the positively charged internal core of nociceptin (8-13) interacts. The image was produced using the SETOR and SETORPLOT programs of Evans (1993). and Val 283 (conserved in the µ-and δ-receptors; isoleucine in the κ-receptor) falling within an inter-residue distance of 5 Å (Table VI) , and Ile219 (valine in all three opioid receptors) just beyond this limit. Reports that excision of F1 from nociceptin yields an inactive (2-17) peptide (Matthes et al., 1996; Butour et al., 1997) can be explained by the model, which does not permit the simultaneous binding of the F4 phenyl ring in its preferred pocket and the hydrogen bonding of a newly protonated G2 N-terminus with Asp130.
Nociceptin-(5-7) binds at the receptor (EL2) loop-transmembrane helix interface. In contrast to the highly conserved nature of the F1 and F4 binding pockets, the only entirely conserved residues within 5 Å of nociceptin-(5-7) are Cys304 and the half-cystines of the disulphide bridge (Table VI) . Prominent amongst the most variable residues is Gln286, lying on the periphery of the F4 pocket where it is able make favourable contacts with the T5 sidechain ( Figure 6 , Table VI ). The respective residue equivalents in the κ-, µ-and δ-opioid receptors are glutamate, lysine and tryptophan, and this residue position is thought to be a likely determinant of κ-opioid receptor specificity (Hjorth et al., 1995; Metzger et al., 1996) . Structure-activity studies using dynorphin A/nociceptin hybrid peptides have identified neuropeptide positions 5 and 6 as being major determinants of ORL1 and κ-opioid receptor selectivity (Lapalu et al., 1997) . The (dn8) hybrid peptide, YGGFLRARKSARKLANQ, comprising L5 and R6 (underlined) dynorphin A replacements for T5 and G6 in the fully functional [Y1]-nociceptin molecule, binds poorly to the ORL1 receptor. In accordance with this finding, inspection of the Fig. 6 . Binding of nociceptin-(1-13) to the ORL1 receptor. The view shows the interaction of nociceptin-(1-13), coloured according to atom type (C, grey; O, red; N, blue), with the extracellular termini of receptor TM helices 3 (Cys123-Met134), 5 (Pro213-Phe224), 6 (Trp276-Gln286) and 7 (Ile300-Asn311) coloured in blue, and segments of the EL2 (Val193-Gly212) and EL3 (Gly287-Val290) loops, depicted as magenta tubes. The disulphide bridge (Cys123-Cys200) is represented in yellow. Selected ORL1 receptor sidechains are coloured according to residue type (acidic, red; basic, blue; polar, green; cysteine and methionine, yellow; tyrosine and tryptophan, crimson; other hydrophobic, burnt orange). Intra-and intermolecular hydrogen bonds involving nociceptin (Table VII) are shown as yellow spheres connecting heavy atom positions. The image was produced using SETOR and processed using SETORPLOT (Evans, 1993). modelled complex reveals that the same double-residue interchange in nociceptin would lead to unacceptable interactions with the receptor. The T5 sidechain finds itself in a partially polar environment, provided by its putative Gln286 partner and Glu295, with which Gln286 can form a hydrogen bond. Modelling of an arginine residue at position 6 would require its sidechain to be positioned in a hydrophobic region between the TM4 (Gly182-Gly189) and TM5 (Gly212-Ile219) helices. Potentially unfavourable sidechain contacts thus make it unlikely that dynorphin A or the (dn8) hybrid would adopt the same conformation as that of nociceptin in the model.
The positively charged nociceptin-(8-13) core mainly interacts with the acidic second extracellular (EL2) loop (see Figure 6 and Table VI). Residues R8 through A11 have been modelled as an α-helix, with the A11 backbone amide donating a hydrogen bond to the carbonyl oxygen of R8. This enables the peptide to pass through the EL2 loop-TM helix interfacial region by orthogonally interlocking with a complementary short helical section (Glu196-Ile198, Cys200) in the EL2 loop, The conformational categorization of irregular structure in (φ, ψ) space is that of Topham et al. (1993) , and the short α-helix (H) is defined according to the secondary structure criteria of Kabsch and Sander (1983) . Interatomic distances were calculated between heavy atoms. Definitions of the receptor structural elements are given in Figure 1 . Fully conserved residues in the opioid receptor family are indicated in bold typeface.
broken by Glu199, falling within the polyproline II-like (p) conformational domain. The presence of charged sidechains at positions 8 and 12 appears particularly critical for nociceptin affinity and activity (Dooley and Houghten, 1996; Reinscheid et al., 1996; Lapalu et al., 1997) . Consistent with this, several putative ion-pairs are made between the sidechains of the four positively charged residues of nociceptin (R8, K9, R12, K13) and the acidic EL2 loop (Figure 6 ). Details of these and other hydrogen bonds involving nociceptin, including a mainchainmainchain intermolecular hydrogen bond from the EL2 loop to the S10 carbonyl oxygen, are summarized in Table VII .
Discussion
Template choice for modelling opioid receptor structural family members Comparative modelling techniques rely on the availability of at least one known protein structure, usually a homologue, comprising the same fold with which the sequence of the unknown can be aligned with some degree of confidence.
Prior to the publication of a 9 Å bovine rhodopsin electron microscopy map (Schertler et al., 1993) , most early GPCR models (reviewed by used the Schertler et al. (1993) projection map and site-directed mutagenesis data, to derive a rhodopsin template conforming to the helix assignments of Baldwin (1993) . An increased tilt in TM helix 5 in the predicted rhodopsin template was found to be consistent with the sharpened 9 Å electron microscopy map of frog rhodopsin published at the same time by Unger and Schertler (1995) . When they applied their method to bacteriorhodopsin, Herzyk and Hubbard (1995) obtained a r.m.s.d. of 1.8 Å with respect to the structure of Henderson et al. (1990) . The general approach, also applied by Pogozheva et al. (1997) to rhodopsin, typifies the increasing use of spatial restraints, derived from a wider knowledge base, in the comparative modelling of globular proteins, reviewed by Sánchez and Š ali (1997) . Together with others, Du et al. (1997) for example, we have used the Herzyk and Hubbard (1995) template as a starting point for GPCR modelling. The ORL1 receptor model described here satisfies the structural requirements imposed by proximity of residue pairs on different TM helices inferred from correlated site-directed mutagenesis studies ( Figure 3 and Table III) . From a functional perspective we find that the five point mutation sites in helices 5 (A216K), 6 (V279I, Q280H, V281I) and 7 (T305I) that suffice to restore a fully responsive transmembrane opioid alkaloid binding site in the ORL receptor , are located within the proposed nociceptin-(1-4) FGGF tetrapepdide binding site (Figure 7 ), conserved to a very high degree in the opioid receptor family (Table VI) . It was therefore with considerable interest that we critically examined the rhodopsin family C α template of Baldwin et al. (1997) , based on the most recent projection structure of frog rhodopsin , released during the later stages of this work.
The major differences between the latest rhodopsin projection map, which has an effective resolution of 7.5 Å in the plane of the membrane , and previous 9 Å maps (Schertler et al., 1993; Unger and Schertler, 1995) , are increased tilts in helices 3 and 5. Superposition of (85) C α coordinate equivalents from TM helices 1, 2, 4, 6 and 7 in the membrane spanning region defined by Baldwin et al. (1997) , yields an r.m.s.d. of 3.0 Å between the liganded ORL1 model and the rhodopsin template, and 3.5 Å for (121) residue equivalents in all seven helices. Examination of the superposed structures reveals that the effect of the tilt changes is largely confined to TM helix 5 in the extracellular half of the bundle. Residues in TM helix 3, such as for example, aspartate 130 within the FGGF 'opioid binding pocket', show limited displacement. TM helix 5 is significantly translated in the membrane plane away from TM helix 6 in this region. Distance limits deduced from correlated site-directed mutagenesis studies of two separate residue clusters located on TM helices 5 and 6 are, however, better met by our model. Hwa et al. (1995) have convincingly demonstrated, on the basis of cooperative ligand binding in mutant receptors, that Ala204 (TM helix 5) and Leu314 (TM helix 6) are in direct contact in the α 1b adrenergic receptor, and contribute to α 1a /α 1b subtype selectivity. Based on a 29% shared sequence identity, the conserved seven-helix cores of the human ORL1 and hamster α 1b adrenergic receptors can be estimated to superpose to an r.m.s.d. of 1.5 Å according to the Chothia and Lesk (1986) formula. This may be regarded as an upper limit since the Chothia and Lesk (1986) relation was derived for globular proteins, and the 2-D constraints imposed by the membrane may permit greater sequence variation. The C β atoms of the equivalent residues in the ORL1 receptor, Ala216 and Val283, are 6.7 and 7.4 Å apart in the liganded receptor and aporeceptor (Table III) , respectively, but are 15.0 Å apart when a backbone is driven through the Baldwin et al. (1997) C α coordinate set. These two residue positions lie within the 'opioid binding pocket', where they form the rear walls of the proposed F4 nociceptin sub-site. The pulling apart of helices 5 and 6 leaves both the F1 and F4 sub-sites partly exposed to lipid.
The second residue cluster, comprising ORL1 residue equivalent sites 212, 216 and 287, lies closer to the external surface at the interface of TM helices 5 and 6 with the C-and N-termini of the EL2 and EL3 loops, respectively. Residue proximity in the equivalent triplet in rhodopsin has been demonstrated using a disulphide mapping technique (Yu et al., 1995) , and in the tachykinin NK1 (Elling et al., 1995 and κ-opioid receptors by the incorporation of histidine residues to create zinc ion binding sites. Geometric considerations would place approximate upper distance bounds of 13 Å between the C α of Gly287 and the C α atoms of Ala216 and Gly212 in the case of a metal binding site (Higaki et al., 1992) . These criteria are met by our model, with interatomic distances of 10.5 and 10.7 Å for Gly287-Ala216 and Gly287-Gly212, respectively (Table III) . The corresponding distances in the rhodopsin template are 13.7 and 16.7 Å when all three residues are in helical conformations, and therefore too long to permit disulphide formation . Baldwin et al. (1997) reason that the three residue positions lie just outside helical elements within the extracellular loop domain of rhodopsin, and probably in other GPCRs as well. However, uncertainties in the positioning of TM helix 5, noted by Unger et al. (1997) as being the least clear feature in the rhodopsin projection map, cannot be ruled out. The apparent discrepancy in the separation of positions 216 and 283 (ORL1 numbering), whose assignment to helical regions is more certain, lends weight to this view. Relative shifts in helix-helix distances and angles are well known in globular protein structures sharing a common architecture (Lesk and Chothia, 1980) , and these observations raise the broader question as to what extent is the tertiary structure of rhodopsin conserved in other GPCRs that do not possess a covalently bound ligand.
Structure-function relationships in the nociceptin-ORL1 and dynorphin A-κ-opioid receptor systems
Mounting evidence indicates that the structural requirements for activation of the nociceptin-ORL1 and dynorphin A-κ-opioid receptor systems are different. Nociceptin-(1-13) is the shortest C-terminal truncated analogue to retain full activity (Dooley and Houghten, 1996; Guerrini et al., 1997) , and the excision of six or less residues from the nociceptin C-terminus abolishes activity (Dooley and Houghten, 1996; Reinscheid et al., 1996; Shimohigashi et al., 1996) . The crucial structural elements conferring nociceptin affinity and activity towards the ORL1 receptor appear to primarily reside within the internal (5-13) TGARKSARK sequence (Dooley and Houghten, 1996; Reinscheid et al., 1996; Lapalu et al., 1997) . In the modelled complex, nociceptin-(5-7) is proposed to bind to the receptor EL2 loop-transmembrane helix interface, and nociceptin-(8-13) to interact predominantly with the EL2 loop (Table VI) . Lapalu et al. (1998) have engineered an ORL1/κ-opioid chimeric receptor (O-K) by replacing structural elements from the N-terminal third of the κ-opioid receptor (residues 1-141) with their ORL1 counterparts (residues 1-133). Whilst the (O-K) hybrid displayed a 300-fold increased affinity for nociceptin compared with the parent κ-opioid receptor, it was still only sluggishly activated by nociceptin. However, Mollereau and co-workers (Mollereau,C., Moulédous,L., Lapalu,S., Cambois,G., Moisand,C., Butour,J.-L. and Meunier, J.-C., manuscript submitted) observe full restoration of both nociceptin affinity and selectivity upon replacement of the EL2 loop in (O-K), originating from the κ-opioid receptor, with that of the ORL1 receptor. This provides firm evidence that the EL2 loop is necessary for activation of the ORL1 receptor by nociceptin. Butour et al. (1997) report that the C-terminal nociceptin-(6-17) fragment binds and activates the ORL1 receptor, further suggesting that the classic N-terminal tetrapeptide (Y/FGGF) opioid 'message' is not an absolute requirement for receptor activation. This conclusion is strengthened by the identification by Dooley et al. (1997) of four potent hexapeptide agonists of the ORL1 receptor with the general form (NAc-RYYX 4 WX 6 -NH 2 ), where X 4 and X 6 can be either R or K. These synthetic peptide agonists together with a fifth (NAc-RYYRIK-NH 2 ) identified in the same study, are likely mimics of the positively charged nociceptin-(8-13) core.
In the case of the κ-opioid receptor, removal of as many as 10 residues from the C-terminus of dynorphin A has been shown to exert a limited effect on binding (Mansour et al., 1995) and activity (Chavkin and Goldstein, 1981) . Moreover the (dn8) hybrid peptide of Lapalu et al. (1997) , in which 11 residues from the C-terminus of dynorphin A have been replaced by those of nociceptin, exhibits essentially the same binding and activity characteristics as dynorphin A towards the κ-opioid receptor. The N-terminal (1-6 or 7) section of dynorphin A thus appears to be sufficient to bestow full functionality towards the κ-opioid receptor, and it may be supposed that interactions of the YGGF N-terminal tetrapeptide 'message' with the transmembrane opiate binding pocket are crucial for activation. However, the nature of interactions of the internal L5-R6 sequence, responsible for the selective preference of the κ-opioid receptor for dynorphin A over nociceptin (Lapalu et al., 1997) , and those of the contiguous positively charged dynorphin A-(6-13) core 'address' (RRIRPKLK) with the receptor remain a matter of conjecture, as does the role of its acidic EL2 loop. On the basis of a model of the κ-opioid receptor-dynorphin A complex, Paterlini et al. (1997) have proposed an activation mechanism, mediated by specific hydrophobic interactions of three dynorphin A residues (F4, L5, I8) with the EL2 loop. Mitigating against such a deterministic mechanism however, are recent observations that the wild-type κ-opioid receptor and the two ORL1/ κ-opioid chimera described above, one comprising the κ-opioid and the other the ORL1 receptor EL2 loop, all possess the same binding and activity characteristics with respect to dynorphin A (Lapalu et al., 1998 ; Mollereau,C., Moulédous,L., Lapalu,S., Cambois,G., Moisand,C., Butour,J.-L. and Meunier, J.-C., manuscript submitted). This shows that the EL2 loop is not absolutely essential for activation of the κ-opioid receptor. Nevertheless studies of κ/µ (Wang et al., 1994b; Xue et al., 1994) and κ/δ (Coward et al., 1998) chimeric receptors have demonstrated contributions of the EL2 loop in κ-opioid receptor selectivity, and its primary functional role may be that of a filter, barring access of µ and δ-selective ligands to the transmembrane opiate binding pocket (Metzger and Ferguson, 1995) .
The emergent picture is one of mutually reciprocating activation mechanisms operating in the ORL1 and κ-opioid receptor systems, with the ORL1 receptor displaying an absolute functional dependence on its EL2 loop, and the κ-opioid receptor on the N-terminal YGGF tetrapeptide opioid binding pocket, conserved to a high degree in the ORL1 receptor as shown by the model. The evolution of an alternative activation mechanism mediated by the extracellular loop domain may thus have relegated the binding of nociceptin-(1-4) in a vestigial opioid binding pocket to a principally locatory function, the free energy of binding being only weakly coupled to receptor activation. Consistent with this is the tolerance of a leucine sidechain at the first position of nociceptin (Guerrini et al., 1997) , implying that the steric requirements for binding in the F1 hydrophobic pocket are not overly strict. Partial decoupling of binding energy in this way can also account for the insensitivity of the ORL1 receptor to many opioid ligands. Meng et al. (1998) report that as few as five point mutations in TM helices 5, 6 and 7 will restore an opioid alkaloid binding site with naltrindole-sensitive, etorphinestimulated [ 35 S]GTPγS binding properties. However it is evident that desensitization is only partial in the wild-type ORL1 receptor, since it does bind and respond to certain opiates, notably lofentanil, to inhibit adenylyl cyclase (Butour et al., 1997) .
Conclusions
The combined technical difficulties of obtaining sufficient quantities of material and the selection of suitable detergent systems for membrane protein crystallization seem likely to delay the experimental determination of the first high resolution three-dimensional GPCR structure for some time (Ostermeier and Michel, 1997) . Computer modelling techniques, when deployed in conjunction with information derived from sitedirected mutagenesis and other experimental strategies, thus afford an attractive alternative with which to probe GPCR functional architecture. We have used this approach to construct a model of the ORL1 receptor and the complex with the endogenous peptide agonist, nociceptin. The C α template of Herzyk and Hubbard (1995) was used as a starting structure to model the seven transmembrane helical bundle. Following rotation of TM helices 2 and 4, and further refinement, the final model satisfied several distance constraints between residues on different helices, inferred from correlated sitedirected mutagenesis experiments in GPCR systems (Table III) . The N-terminal FGGF tetrapeptide of nociceptin is proposed to bind in a highly conserved transmembrane region, comprising elements from helices 3, 5, 6 and 7, that is the topological equivalent of the opioid binding pocket in the κ-, δ-and µ-receptors. Two distinct hydrophobic pockets accommodating the sidechains of phenylalanines 1 and 4 have been identified. These pockets are also present in the TM bundle modelled directly from the recent rhodopsin family C a template of Baldwin et al. (1997) , largely based on the projection map of Unger et al. (1997) . They are, however, considerably more capacious and partly exposed to lipid due to the looser packing of helices 5 and 6 forming the rear wall of the F1 and F4 subsites. The origins of this appear to lie primarily in the positioning of helix 5, a view reinforced by the finding that two sets of distance limits involving residue clusters at the top of TM helices 5 and 6 are poorly satisfied. To what extent these structural differences are peculiar to the rhodopsin family remains unclear, but a re-positioning of TM helix 5 would appear necessary for the Baldwin et al. (1997) template to be suitable for modelling of the opioid receptor family.
Nociceptin-(5-7) binds at the receptor (EL2) loop-transmembrane helix interface in a largely non-conserved region, as might be expected from structure-activity studies that show neuropeptide positions 5 and 6 to be major determinants of ORL1 and κ-opioid receptor selectivity (Lapalu et al., 1997) . Potentially unfavourable sidechain contacts in this part of the extended peptide binding site appear to rule out binding of dynorphin A in the same conformation as that of nociceptin. Studies of κ-opioid-ORL1 chimeric receptors demonstrate that the EL2 loop is essential for activation of the ORL1 receptor by nociceptin (Mollereau,C., Moulédous,L., Lapalu,S., Cambois,G., Moisand,C., Butour,J.-L. and Meunier,J.-C., manuscript submitted). The model shows that the basic (RKSARK) nociceptin-(8-13) core, also a necessary requirement for activation (Dooley and Houghten, 1996; Reinscheid et al., 1996; Lapalu et al., 1997) , is able to establish multiple interactions with the acidic EL2 loop. The finding that the Nterminal tetrapeptide is not an absolute requirement for ORL1 receptor activation (Butour et al., 1997) , together with the identification by Dooley et al. (1997) of potent cationic hexapeptide agonists that probably mimic the nociceptin-(8-13) core, suggests that the binding energy contributed by nociceptin-(1-4) may be partially decoupled from activation mediated by the EL2 loop. Interactions of the N-terminal FGGF tetrapeptide in a vestigal opioid pocket may therefore serve a more locatory function, consistent with the poor activation properties of many opiates towards the ORL1 receptor.
